{"id":"tislelizumab-neoadjuvant","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab binds to programmed death receptor 1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells. This blockade reverses T cell exhaustion and enhances cytotoxic T cell proliferation and activation against cancer cells. In the neoadjuvant setting, it is administered prior to surgical resection to improve pathological response and potentially enhance long-term outcomes.","oneSentence":"Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:55.727Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC)"},{"name":"Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCC)"}]},"trialDetails":[{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT07475026","phase":"PHASE3","title":"A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-05-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":198},{"nctId":"NCT07458529","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Seventh Medical Center of PLA General Hospital","startDate":"2026-02-10","conditions":"Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy","enrollment":50},{"nctId":"NCT06647680","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-06-01","conditions":"Rectal Cancer Patients","enrollment":35},{"nctId":"NCT07425795","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-10","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":36},{"nctId":"NCT07352280","phase":"","title":"Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-01","conditions":"Colo-rectal Cancer (dMMR/MSI-H CRC)","enrollment":30},{"nctId":"NCT05116085","phase":"PHASE2","title":"Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2022-01-26","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT05577702","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-03-08","conditions":"Non Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT07373990","phase":"PHASE3","title":"Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-15","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":418},{"nctId":"NCT06764355","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-07-23","conditions":"ESCC, Total Neoadjuvant Treatment, Pathological Complete Response","enrollment":50},{"nctId":"NCT07370337","phase":"PHASE2","title":"Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-05-12","conditions":"Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced Tumor","enrollment":50},{"nctId":"NCT07353294","phase":"PHASE1","title":"Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Bladder Urothelial Carcinoma, Lymph Node Metastasis","enrollment":12},{"nctId":"NCT07346807","phase":"PHASE2","title":"Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-01","conditions":"Tongue Squamous Cell Carcinoma","enrollment":69},{"nctId":"NCT06312982","phase":"PHASE2, PHASE3","title":"A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-03-16","conditions":"Locally Advanced Rectal Carcinoma","enrollment":375},{"nctId":"NCT07050056","phase":"PHASE2","title":"Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2025-08-01","conditions":"Resectable NSCLC","enrollment":20},{"nctId":"NCT07330037","phase":"PHASE2","title":"TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC","enrollment":41},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT06877299","phase":"PHASE2","title":"Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-04","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05837806","phase":"PHASE2","title":"Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2022-12-30","conditions":"Neoadjuvant Immunotherapy","enrollment":21},{"nctId":"NCT06494189","phase":"PHASE1","title":"Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2024-07-31","conditions":"Head and Neck Cancer","enrollment":9},{"nctId":"NCT07040956","phase":"PHASE2","title":"A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-28","conditions":"Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy","enrollment":98},{"nctId":"NCT07297030","phase":"PHASE2","title":"SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-20","conditions":"Rectal Cancer","enrollment":37},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT07059299","phase":"PHASE1","title":"A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-12-12","conditions":"Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":18},{"nctId":"NCT07271992","phase":"PHASE2","title":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2025-12-15","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT05508399","phase":"","title":"Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2022-07-18","conditions":"Locally Advanced Gastric Adenocarcinoma, PD-1","enrollment":28},{"nctId":"NCT07264647","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2025-03-27","conditions":"Stage III NSCLC","enrollment":30},{"nctId":"NCT06914011","phase":"PHASE3","title":"Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-01-06","conditions":"Esophageal Cancer","enrollment":172},{"nctId":"NCT04974047","phase":"PHASE2","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-17","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT05507658","phase":"PHASE2","title":"Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2022-07-18","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":28},{"nctId":"NCT07248696","phase":"NA","title":"Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":32},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT06804850","phase":"PHASE2","title":"Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC","status":"WITHDRAWN","sponsor":"West China Hospital","startDate":"2025-01-20","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT07231575","phase":"PHASE2","title":"Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-10","conditions":"Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy","enrollment":39},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT06467799","phase":"PHASE2","title":"Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma, Beyond Milan Criteria","enrollment":39},{"nctId":"NCT06838208","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-02-25","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":56},{"nctId":"NCT06124378","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-11-13","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":60},{"nctId":"NCT04047186","phase":"PHASE2","title":"Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules","status":"COMPLETED","sponsor":"XiangNing Fu","startDate":"2019-07-01","conditions":"Multiple Pulmonary Nodules","enrollment":12},{"nctId":"NCT07111455","phase":"","title":"Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-07-22","conditions":"Locally Advanced Oral Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT06826079","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-01","conditions":"Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy","enrollment":80},{"nctId":"NCT06884670","phase":"PHASE2","title":"Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-18","conditions":"Rectal Cancer","enrollment":130},{"nctId":"NCT05758389","phase":"PHASE2","title":"Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-04-01","conditions":"Head and Neck Tumors","enrollment":29},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT07147426","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-09-20","conditions":"Head &Amp; Neck Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT06794073","phase":"NA","title":"Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-09-01","conditions":"Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Adenocarcinoma","enrollment":17},{"nctId":"NCT07145931","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy","enrollment":24},{"nctId":"NCT05880082","phase":"PHASE2","title":"PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-01-13","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT05515796","phase":"PHASE2","title":"Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2022-09-01","conditions":"Immunotherapy, Gastric Cancer, Rectal Cancer","enrollment":200},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT07132463","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Rectal Cancer","enrollment":154},{"nctId":"NCT07126119","phase":"PHASE2","title":"Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2025-07-05","conditions":"Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor","enrollment":35},{"nctId":"NCT07125547","phase":"PHASE2","title":"Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2025-07-05","conditions":"Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor","enrollment":35},{"nctId":"NCT07119996","phase":"PHASE1","title":"Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":12},{"nctId":"NCT06364956","phase":"PHASE1, PHASE2","title":"Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-05-15","conditions":"Bladder Cancer","enrollment":36},{"nctId":"NCT07104604","phase":"PHASE1","title":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2025-08-01","conditions":"Rectal Cancer","enrollment":59},{"nctId":"NCT07109401","phase":"PHASE2","title":"Perioperative Immunotherapy for Resectable Limited-Stage SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT04570410","phase":"PHASE2","title":"Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-12-01","conditions":"Bladder Urothelial Carcinoma","enrollment":30},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT05517330","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-19","conditions":"Head and Neck Cancer","enrollment":23},{"nctId":"NCT07089199","phase":"PHASE2","title":"Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-25","conditions":"NSCLC, Tislelizumab, Anlotinib","enrollment":34},{"nctId":"NCT06734702","phase":"PHASE3","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":497},{"nctId":"NCT06940388","phase":"PHASE2","title":"Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.","status":"RECRUITING","sponsor":"brenner baruch","startDate":"2025-07-23","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":134},{"nctId":"NCT05604560","phase":"PHASE2","title":"A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lei Zheng","startDate":"2023-11-08","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT07070622","phase":"PHASE3","title":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"Rectal Cancer","enrollment":186},{"nctId":"NCT07067450","phase":"NA","title":"Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-20","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":98},{"nctId":"NCT07068178","phase":"PHASE2","title":"Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"Jing Li","startDate":"2025-08","conditions":"HIPEC, Ovarian Serous Adenocarcinoma","enrollment":30},{"nctId":"NCT06617936","phase":"PHASE2","title":"Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"Hua Zhang","startDate":"2024-08-27","conditions":"Unresectable Non-small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04833257","phase":"PHASE2","title":"Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-04-14","conditions":"Nasopharyngeal Carcinoma","enrollment":63},{"nctId":"NCT06977828","phase":"PHASE2","title":"A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-07-20","conditions":"NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy","enrollment":40},{"nctId":"NCT06829641","phase":"","title":"Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-08-09","conditions":"NSCLC Stage IIIB, NSCLC Stage IIIC","enrollment":200},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT07010120","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-10","conditions":"HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy","enrollment":29},{"nctId":"NCT05319574","phase":"PHASE2","title":"SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-04-24","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":46},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT06446726","phase":"PHASE2","title":"Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-06-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06598527","phase":"PHASE3","title":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study","status":"RECRUITING","sponsor":"Yang Hong","startDate":"2024-10-15","conditions":"Lung Cancer (NSCLC)","enrollment":360},{"nctId":"NCT05941481","phase":"PHASE2","title":"Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2023-06-10","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":21},{"nctId":"NCT06990178","phase":"NA","title":"Adaptive Neoadjuvant Therapy for Esophageal Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2028-03-01","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT06977074","phase":"PHASE2","title":"PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-10","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":83},{"nctId":"NCT05516589","phase":"PHASE2","title":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06965829","phase":"PHASE2","title":"The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Esophageal Cancer Stage III","enrollment":40},{"nctId":"NCT06957938","phase":"PHASE3","title":"Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-28","conditions":"Laryngeal Carcinoma, Hypopharyngeal Carcinoma","enrollment":168},{"nctId":"NCT06420440","phase":"PHASE2","title":"Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model","status":"RECRUITING","sponsor":"Chen Xiaoping","startDate":"2024-06-01","conditions":"HCC","enrollment":160},{"nctId":"NCT06939127","phase":"PHASE2","title":"Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":38},{"nctId":"NCT06673693","phase":"PHASE2","title":"Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC","enrollment":24},{"nctId":"NCT06916494","phase":"PHASE1","title":"Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-05-01","conditions":"Muscle Invasive Bladder Cancer","enrollment":10},{"nctId":"NCT06908733","phase":"PHASE2","title":"Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer (Stage III)","enrollment":30},{"nctId":"NCT06056804","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-01-03","conditions":"Locally Advanced Rectal Cancer","enrollment":20},{"nctId":"NCT06903273","phase":"PHASE2","title":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Biliary Tract Cancer (BTC)","enrollment":35},{"nctId":"NCT06881537","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06-01","conditions":"Locally Recurrent Colorectal Cancer","enrollment":15},{"nctId":"NCT05223088","phase":"PHASE2","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-10-31","conditions":"Immunotherapy, Gastrict Cancer","enrollment":40},{"nctId":"NCT06258811","phase":"PHASE3","title":"Neoadjuvant Immunochemotherapy for LAOSCC","status":"RECRUITING","sponsor":"Lai-ping Zhong","startDate":"2024-02-20","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma","enrollment":134},{"nctId":"NCT06692270","phase":"PHASE2","title":"Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-05-15","conditions":"Esophagus Cancer","enrollment":20},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT05920863","phase":"PHASE2","title":"Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-07-01","conditions":"Hepatocellular Carcinoma, Lenvatinib, Tislelizumab","enrollment":35},{"nctId":"NCT05557578","phase":"PHASE2","title":"GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-05-05","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":133,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tislelizumab（neoadjuvant）","genericName":"Tislelizumab（neoadjuvant）","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC), Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}